🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareGLP-1 therapy in patients over 65 — safety and efficacy data Page 5

GLP-1 therapy in patients over 65 — safety and efficacy data

GraceAZ_72 Thu, Jan 8, 2026 at 11:59 AM 40 replies 1,293 viewsPage 5 of 8
MounjBrad
Member
278
890
Oct 2024
Kentucky
Jan 8, 2026 at 7:04 PM#21

Just wanted to say — for anyone reading this GLP-1 therapy in thread who is feeling discouraged: it gets better. The first few weeks are the hardest. Hang in there. 💪

Last edited: Jan 9, 2026 at 12:04 AM
9 18patPC_UT, Dr.DermMIA, fiona_VT and 6 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Jan 8, 2026 at 7:21 PM#22

Want to share my personal experience related to GLP-1 therapy in patients over since I think it might help others in a similar situation.

I started my GLP-1 journey in October 2024 at 256 lbs with prediabetes and hypertension. My endocrinologist prescribed semaglutide 0.25mg to start.

Now, 16 months later: I am down 51 lbs, my labs have normalized, and I am off 2 of my 3 medications. The GLP-1 therapy in aspect specifically was something that made a big difference in my journey.

This community helped me every step of the way.

20 19PharmHunterJen, TomTeleRx, DoseLogDan and 17 others
Reply Quote Save Share Report
hyun_seoul
Member
345
1,456
Jul 2024
Seoul, KR
Jan 8, 2026 at 7:38 PM#23

Clinical perspective on GLP-1 therapy in patients over 65 :

I have managed ~150 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that proper titration prevents most adverse events.

For this specific question, I would recommend: reviewing the relevant clinical guidelines.

19 11MASHdoc_SA, GenomicsKate, Dr.ObesityMed and 16 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Jan 8, 2026 at 7:55 PM#24

Thank you TrialNerd_Beth! This is incredibly helpful. Taking this to my next appointment. 🙏

8 10oliver_london, tane_welly, Dr.PathRoch and 5 others
Reply Quote Save Share Report
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Jan 8, 2026 at 8:12 PM#25

Relevant to GLP-1 therapy in patients over — here is my latest bloodwork comparison:

Key improvements: A1C 8.0% → 5.3%, triglycerides 219 → 119 mg/dL, hsCRP 6.0 → 1.3 mg/L. All on tirzepatide for 11 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Last edited: Jan 9, 2026 at 1:12 AM
8 18Dr.EndoEP, GraceAZ_72, carl_compliance and 5 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register